space123 wrote:
輝瑞連結內容：BNT162b2...(恕刪)
幫您補一下腦:
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine
https://www.businesswire.com/news/home/20201118005595/en/
Pfizer/BIONTECH 去年11月三期解盲，第三期約有43000人參與，分散在6個國家裡。
The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate as of November 13, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds, and 41% of global and 45% of U.S. participants are 56-85 years of age. A breakdown of the diversity of clinical trial participants can be found here from approximately 150 clinical trials sites in United States, Germany, Turkey, South Africa, Brazil and Argentina. The trial will continue to collect efficacy and safety data in participants for an additional two years.
Mission Possible: The Race for a Vaccine
Science will win !!!
